3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA

US10676499B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• David Barnes-Seeman · Cambridge, US
• Scott Louis Cohen · Peabody, US
• John Diener · Cambridge, US
• Christian M. Gampe · Watertown, US
• James ROACHE · Cambridge, US
• Amy White · Warrenton, US
• Sarah Williams · Emeryville, US
• Jun Yuan · Guilford, US
• Frederic Zecri · Cambridge, US

Key dates

• Filing date: Dec 16, 2015
• Grant date: Jun 9, 2020
• Expiry date: Dec 16, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/5759
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.